Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Sinochem Pharmaceuticals is all set to establish a new production facility for new Semi-Synthetic Cephalosporins (SSC), in Zibo's High & New Technology Development Zone in China.
Subscribe to our email newsletter
The production of SSC is said to make use of the company’s proprietary biotechnology which will reduce energy consumption by
66%, produce 90% less waste and have 50% less emissions to air, compared to the chemical process.
According to the company, the new project would boost their growth strategy and enforce the beta-lactam business besides expanding its portfolio of Active Pharmaceutical Ingredients.
The facility that will serve both the Chinese and the export market is likely to begin operations in early 2013.
DSM Sinochem China Business Unit Director Hu Jian said the new investment suits the strategy to build their current SSCs business and broaden the product portfolio.
"Exactly 2 years after we have opened a similar facility for the enzymatic production of 1st generation Cephalosporins here in Zibo, this is the natural next step in rolling out the advantages of our enzymatic production processes for pharmaceutical AIs to next generation products," Jian added.